Ilant Health has raised $15 million in Series A funding to expand its value-based obesity care model, bringing the company’s total funding to more than $22 million. The New York-based company said the round was led by Cornucopian Capital, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, and existing backers Celtic, LifeX, and AlphaLab. The financing comes as employers and health plans face growing pressure to manage rising obesity-related healthcare costs while improving access to effective, evidence-based treatment.
Building a More Coordinated Model for Obesity Care
Founded by Elina Onitskansky, a former McKinsey and Molina Healthcare executive, Ilant Health works with employers and health plans to deliver clinician-led obesity and cardiometabolic care. The company positions itself as an AI-enabled healthcare services provider, using clinical, behavioral, and personal data to match individuals with tailored treatment pathways. Its model is designed to replace fragmented point solutions with continuous care that evolves as each member responds to treatment.
Ilant’s approach includes behavioral therapy, medication, and surgical options, supported by broader interventions addressing nutrition, physical activity, stress, and overall health. The company said its treatment pathways may include GLP-1 and non-GLP-1 therapies, depending on individual needs and clinical appropriateness. By combining medical care with data-driven personalization, Ilant aims to deliver measurable outcomes rather than simply expanding access to isolated treatments.
Early Results and Employer Demand
According to the company, early outcomes show members achieving an average weight loss of 15%, significantly above the 5.8% reported in real-world settings cited in the announcement. Ilant also reported improvements in broader health measures and wellbeing, including an average increase of two mentally healthy days per month among members. The company says these outcomes demonstrate its ability to deliver clinically meaningful results while helping employers and payers manage total cost of care.
Demand for more integrated obesity care models is rising as organizations weigh the clinical benefits of newer obesity medicines against rapidly increasing pharmacy costs. Ilant said it is already working with employers and healthcare partners seeking alternatives to narrow medication-only programs or restrictive cost-control strategies. Kenneth L. Gardner, Director of Growth, Benefit Operations at SEIU 775 Benefits Group, said Ilant’s population analysis and personalized care model provided confidence in both member outcomes and return on investment.
Addressing the Cost Challenge Around Obesity Medicines
The announcement also follows Ilant’s November 2025 move to introduce direct contracting and transparent pricing solutions for obesity management medications through Lilly’s Employer Connect program. The company said it is also working with Novo Nordisk, giving employers more visibility into pricing and flexibility in benefit design. These arrangements are intended to help employers control one of the fastest-growing categories of healthcare spending while maintaining access to appropriate treatment.
Onitskansky said employers and health plans are caught between expanding access to treatment and absorbing steep pharmaceutical costs, or limiting access and risking worsening chronic disease. She argued that the healthcare system cannot solve the obesity crisis by paying more for disconnected services that fail to improve long-term outcomes. Ilant’s value-based model, she said, is focused on delivering meaningful care while making treatment costs more predictable and sustainable.
Investor Confidence in Outcomes-Based Care
Cornucopian Capital’s founder and managing partner, Aryeh Ganz, said the next generation of healthcare companies will be defined by their ability to deliver outcomes as a service rather than tools or access alone. He said Ilant is applying that principle to one of healthcare’s most expensive and consequential categories. In his view, the future of obesity and cardiometabolic care will depend on matching the right care to the right patient at the right time, rather than relying on a single drug class.
The funding reflects broader investor interest in healthcare models that combine clinical rigor, personalization, and financial accountability. As GLP-1 adoption accelerates, employers and health plans are looking for infrastructure that can support appropriate use, member engagement, and measurable results. Ilant’s pitch is that precision care can improve health outcomes while reducing avoidable spending across obesity-related conditions.
With its latest funding, Ilant Health plans to further scale its AI-supported, clinician-led obesity care model for employers and payers. The company is entering a market where demand for effective obesity treatment is growing quickly, but where cost pressures are intensifying just as fast. By focusing on value-based, personalized care, Ilant is positioning itself as a solution for organizations seeking better outcomes, stronger cost control, and a more coordinated approach to obesity and cardiometabolic health.